Chih-Lin Lin
Overview
Explore the profile of Chih-Lin Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
2044
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang H, Zeng Y, Huang C, Chen C, Kuo H, Tseng K, et al.
J Formos Med Assoc
. 2025 Mar;
PMID: 40023754
Purpose: This study investigated whether Fibrosis-4 (FIB-4) score and its change can serve as predictors of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C (CHC) infection receiving direct-acting...
2.
Chang Y, Lee J, Chen C, Kao W, Lin C, Yang S, et al.
Aliment Pharmacol Ther
. 2025 Feb;
PMID: 39981689
Background: Data regarding the risk of incident type 2 diabetes (T2D) and prediabetes among patients with hepatitis C virus (HCV) achieving direct-acting antivirals (DAAs)-induced sustained virologic response (SVR) remains limited....
3.
Wang S, Wang S, Huang C, Chang T, Chang T, Lo C, et al.
Kaohsiung J Med Sci
. 2025 Jan;
41(2):e12929.
PMID: 39829106
An 8-week regimen of glecaprevir/pibrentasvir is recommended for treatment-naïve patients with chronic hepatitis C (CHC). In alignment with the Taiwanese government's objective to eliminate hepatitis C by 2025, this study...
4.
Hong C, Su T, Hsu S, Tseng T, Liu C, Yang H, et al.
J Formos Med Assoc
. 2024 Nov;
PMID: 39488497
Background And Aims: Direct-acting antiviral agents (DAAs) achieve high sustained virologic response (SVR) in chronic hepatitis C patients; yet a proportion of patients still experience de novo liver complications after...
5.
Liu W, Wu W, Lin C, Liu C, Huang Y, Hu J, et al.
J Gastroenterol
. 2024 Oct;
60(1):107-117.
PMID: 39438326
Background: The effects of age at HBsAg seroclearance on clinical outcomes and survival in chronic hepatitis B (CHB) have not been adequately assessed. We evaluated the impact of age at...
6.
Liu C, Cheng P, Fang Y, Chen C, Kao W, Lin C, et al.
J Hepatol
. 2024 Oct;
PMID: 39368711
Background & Aims: Data are limited on the risk of de novo hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) after achieving sustained virologic response at...
7.
Jang T, Huang C, Chang T, Yang C, Lo C, Hung C, et al.
J Formos Med Assoc
. 2024 Aug;
PMID: 39168745
Background/aims: Hepatitis C virus (HCV) eradication using antiviral agents augments the metabolic profile. Changes in glycated hemoglobin (HbA1c) levels in chronic hepatitis C patients who receive glecaprevir/pibrentasvir (GLE/PIB) remain elusive....
8.
Yu M, Wu W, Lin C, Liu C, Peng W, Huang P, et al.
Hepatol Res
. 2024 Aug;
PMID: 39158502
Aim: To examine the dynamic change in hepatic steatosis status during repeated assessments over time, and its potential impact on the risk of developing cardiovascular disease (CVD). Methods: We assessed...
9.
Chang C, Hsu W, Tseng K, Chen C, Cheng P, Hung C, et al.
Dig Dis Sci
. 2024 Jul;
69(9):3501-3512.
PMID: 38965159
Background: Chronic hepatitis C (CHC) increases the risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). This nationwide cohort study assessed the effectiveness of viral eradication of CHC. Methods: The...
10.
Lin C, Kao J
Clin Liver Dis (Hoboken)
. 2024 Jun;
23(1):e0228.
PMID: 38872773
No abstract available.